Ulcerative Colitis
📧 Sign up to get email alerts when something new happens for Ulcerative Colitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-12-14FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) filed by Pfizer Laboratories Div Pfizer Inc, enabling the extended-rele…
-
CLINICAL_TRIALS trial_result · 2017-12-14Clinical Trial Update: Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis [Phase 2]
Phase 2 pilot study evaluating green tea extract (Polyphenon E) for mild to moderately active ulcerative colitis has completed with results …
-
CLINICAL_TRIALS research · 2017-12-08Clinical Trial Update: Immunological Profiles in Inflammatory Bowel Disease
This clinical trial update describes a study of immunological profiles in inflammatory bowel disease, including Crohn's disease and ulcerati…
-
CLINICAL_TRIALS trial_result · 2017-12-07Clinical Trial Update: Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort
This clinical trial update reports the completion of a longitudinal cohort study on autoimmune paradoxical reactions in inflammatory bowel d…
-
CLINICAL_TRIALS trial_result · 2017-10-27Clinical Trial Update: Golimumab Dried Blood Spot Analysis [Phase 4]
Phase 4 trial update on golimumab examining dried blood spot analysis. The study targets Ulcerative Colitis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2017-10-27Clinical Trial Update: Prevalence of Graves Disease in Patients With Ulcerative Colitis
Clinical trial update examining the prevalence of Graves' disease among patients with ulcerative colitis. The current study status is unknow…
-
CLINICAL_TRIALS trial_result · 2017-10-26Clinical Trial Update: Clinical Outcome After Escalation and De-escalation of Adalimumab in Real Life in Ulcerative Colitis
The update reports clinical outcomes for ulcerative colitis patients managed with escalation and de-escalation of adalimumab in real-world c…
-
CLINICAL_TRIALS research · 2017-10-26Clinical Trial Update: SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins
This entry reports a clinical trial (SSAT 054) investigating non-genetic factors in the pathogenesis of inflammatory bowel disease in twins,…
-
CLINICAL_TRIALS trial_result · 2017-10-20Clinical Trial Update: Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis [Phase 1]
Phase 1 single ascending dose and multiple ascending dose study in healthy volunteers and ulcerative colitis patients; the trial has been te…
-
FDA approval · 2017-10-17FDA Approved: BUDESONIDE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for Budesonide submitted by Padagis US LLC, expanding regulatory authorization for the product. The …
-
FDA approval · 2017-10-13FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for ustekinumab (Stelara) from Janssen Biotech, Inc., potentially expanding indications or updat…
-
CLINICAL_TRIALS trial_result · 2017-10-13Clinical Trial Update: Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) [Phase 4]
Phase 4 clinical trial update evaluating golimumab (MK-8259) utilization and impact in ulcerative colitis with completed results.
-
CLINICAL_TRIALS trial_result · 2017-10-13Clinical Trial Update: Comparison of the Performance of SB2-Infliximab With Originator Infliximab in the Measure of Serum Concentrations in Serum
The document summarizes a clinical trial comparing the pharmacokinetic performance of the biosimilar SB2-infliximab to the originator inflix…
-
CLINICAL_TRIALS trial_result · 2017-10-11Clinical Trial Update: An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase [Phase 3]
A Phase 3 trial evaluating the efficacy and safety of PENTASA in Chinese patients with left-sided active ulcerative colitis has completed, i…
-
CLINICAL_TRIALS trial_result · 2017-09-25Clinical Trial Update: The NOR-SWITCH Study [Phase 4]
Phase 4 clinical trial update for NOR-SWITCH study; completed with multiple inflammatory diseases assessed.
-
CLINICAL_TRIALS trial_result · 2017-09-06Clinical Trial Update: Fecal Microbiota Transplantation in Ulcerative Colitis [Phase 2]
Phase 2 clinical trial update on fecal microbiota transplantation for ulcerative colitis.
-
CLINICAL_TRIALS trial_result · 2017-08-25Clinical Trial Update: Manitoba Inflammatory Bowel Disease Cohort Study
Clinical trial update shows the Manitoba inflammatory bowel disease cohort study is completed, focusing on Crohn's disease and Ulcerative co…
-
CLINICAL_TRIALS trial_result · 2017-08-24Clinical Trial Update: Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis [Phase 2]
Phase 2 trial of QBECO for moderate-to-severe ulcerative colitis has completed, reporting on safety and efficacy outcomes.
-
FDA label_change · 2017-08-22FDA Approved: PENTASA — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for PENTASA (mesalamine) submitted by Takeda Pharmaceuticals America, resulting in an update to the …
-
FDA label_change · 2017-08-22FDA Approved: LIALDA — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for LIALDA (mesalamine) from Takeda Pharmaceuticals America, Inc. This approval results in chang…
-
CLINICAL_TRIALS research · 2017-08-14Clinical Trial Update: An Explanatory Factors Analysis of Inflammatory Bowel Diseases(IBD's) Management Costs for Adults Patients Treated by Biotherapy and Followed at Nancy University Hospital
A completed clinical study analyzing factors that influence the management costs for adults with inflammatory bowel disease treated with bio…
-
CLINICAL_TRIALS research · 2017-07-28Clinical Trial Update: Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis [NA]
Clinical trial update for amino acids in ileal pouch-anal anastomosis for ulcerative colitis; status is unknown.
-
FDA approval · 2017-07-27FDA Approved: CANASA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for CANASA (mesalamine) by Allergan, Inc., expanding or updating its labeling.
-
FDA approval · 2017-07-27FDA Approved: MESALAMINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for mesalamine filed by ANI Pharmaceuticals, Inc.
-
FDA approval · 2017-07-27FDA Approved: MESALAMINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Mesalamine from Teva Pharmaceuticals USA, Inc.